Neuropharmacological Properties of the Essential Oil of Bergamot for the Clinical Management of Pain-Related BPSDs

Author(s): Damiana Scuteri , Laura Rombolá , Laura Tridico , Hirokazu Mizoguchi , Chizuko Watanabe , Tsukasa Sakurada , Shinobu Sakurada , Maria T. Corasaniti , Giacinto Bagetta , Luigi A. Morrone* .

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 20 , 2019

  Journal Home
Translate in Chinese

Abstract:

Background: Alzheimer’s Disease (AD) accounts for approximately 50% of all cases of dementia and, in spite of the great effort for the development of disease-modifying drugs, a definitive treatment of cognitive impairment is not available yet. A perfect adherence to the current therapy of cognitive decline is needed for a better control of the disease and this is proven to reduce, though not completely abolish, the associated Behavioural and Psychological Symptoms of Dementia (BPSDs) from occurring. This cluster of symptoms, remarkably affecting patients’ health-related quality of life (HRQL), is tightly associated with pain states. Antipsychotics are the only treatment for BPSDs. However, these drugs are more effective and safer in the short-term (6-12 weeks), they are able to manage aggression but not agitation and they cannot control pain. Aromatherapy with Melissa officinalis and Lavandula officinalis has been employed to handle BPSDs, but it has not provided strong evidence to offer relief from pain.

Objective: Bergamot Essential Oil (BEO) exerts antinociceptive activity through several pharmacological mechanisms: in particular, it is able to enhance autophagy, a process undergoing derangement in chronic pain. Thus, the sound pharmacological basis for clinical translation of aromatherapy with BEO in the treatment of BPSDs has been pointed out.

Conclusion: The antinociceptive effects elicited by BEO in experimental pain models make it a possible candidate for the pharmacological management of pain-related BPSDs.

Keywords: Aromatherapy, bergamot essential oil, Alzheimer’s disease, dementia, behavioural and psychological symptoms of dementia (BPSDs), pain.

[1]
Prince, M.W.A.; Guerchet, M.; Ali, G.C.; Wu, Y.; Prina, A.M. World Alzheimer Report 2015: The global impact of dementia. An analysis of prevalence, incidence, costs and trends; Alzheimer’s Disease International: London, 2015.
[2]
Winblad, B.; Amouyel, P.; Andrieu, S.; Ballard, C.; Brayne, C.; Brodaty, H.; Cedazo-Minguez, A.; Dubois, B.; Edvardsson, D.; Feldman, H.; Fratiglioni, L.; Frisoni, G.B.; Gauthier, S.; Georges, J.; Graff, C.; Iqbal, K.; Jessen, F.; Johansson, G.; Jönsson, L.; Kivipelto, M.; Knapp, M.; Mangialasche, F.; Melis, R.; Nordberg, A.; Rikkert, M.O.; Qiu, C.; Sakmar, T.P.; Scheltens, P.; Schneider, L.S.; Sperling, R.; Tjernberg, L.O.; Waldemar, G.; Wimo, A.; Zetterberg, H. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol., 2016, 15(5), 455-532.
[http://dx.doi.org/10.1016/S1474-4422(16)00062-4] [PMID: 26987701]
[3]
Jarvik, G.; Larson, E.B.; Goddard, K.; Schellenberg, G.D.; Wijsman, E.M. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am. J. Hum. Genet., 1996, 58(1), 191-200.
[PMID: 8554056]
[4]
Slooter, A.J.; Cruts, M.; Kalmijn, S.; Hofman, A.; Breteler, M.M.; Van Broeckhoven, C.; van Duijn, C.M. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Arch. Neurol., 1998, 55(7), 964-968.
[http://dx.doi.org/10.1001/archneur.55.7.964] [PMID: 9678314]
[5]
Chartier-Harlin, M.C.; Parfitt, M.; Legrain, S.; Pérez-Tur, J.; Brousseau, T.; Evans, A.; Berr, C.; Vidal, O.; Roques, P.; Gourlet, V. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet., 1994, 3(4), 569-574.
[http://dx.doi.org/10.1093/hmg/3.4.569] [PMID: 8069300]
[6]
Swaab, D.F.; Dubelaar, E.J.; Hofman, M.A.; Scherder, E.J.; van Someren, E.J.; Verwer, R.W. Brain aging and Alzheimer’s disease; use it or lose it. In: Prog. Brain Res; , 2002; 138, pp. 343-373.
[http://dx.doi.org/10.1016/S0079-6123(02)38086-5] [PMID: 12432778]
[7]
Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; O’Gorman, J.; Qian, F.; Arastu, M.; Li, M.; Chollate, S.; Brennan, M.S.; Quintero-Monzon, O.; Scannevin, R.H.; Arnold, H.M.; Engber, T.; Rhodes, K.; Ferrero, J.; Hang, Y.; Mikulskis, A.; Grimm, J.; Hock, C.; Nitsch, R.M.; Sandrock, A. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 2016, 537(7618), 50-56.
[http://dx.doi.org/10.1038/nature19323] [PMID: 27582220]
[8]
Lyketsos, C.G.; Steinberg, M.; Tschanz, J.T.; Norton, M.C.; Steffens, D.C.; Breitner, J.C. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry, 2000, 157(5), 708-714.
[http://dx.doi.org/10.1176/appi.ajp.157.5.708] [PMID: 10784462]
[9]
Ballard, C.; Corbett, A. Agitation and aggression in people with Alzheimer’s disease. Curr. Opin. Psychiatry, 2013, 26(3), 252-259.
[http://dx.doi.org/10.1097/YCO.0b013e32835f414b] [PMID: 23528917]
[10]
Margallo-Lana, M.; Swann, A.; O’Brien, J.; Fairbairn, A.; Reichelt, K.; Potkins, D.; Mynt, P.; Ballard, C. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int. J. Geriatr. Psychiatry, 2001, 16(1), 39-44.
[http://dx.doi.org/10.1002/1099-1166(200101)16:1<39:AID-GPS269>3.0.CO;2-F] [PMID: 11180484]
[11]
Kozman, M.N.; Wattis, J.; Curran, S. Pharmacological management of behavioural and psychological disturbance in dementia. Hum. Psychopharmacol., 2006, 21(1), 1-12.
[http://dx.doi.org/10.1002/hup.745] [PMID: 16389667]
[12]
Hersch, E.C.; Falzgraf, S. Management of the behavioral and psychological symptoms of dementia. Clin. Interv. Aging, 2007, 2(4), 611-621.
[http://dx.doi.org/10.1007/s11920-019-1049-5] [PMID: 18225462]
[13]
Finkel, S.I. Behavioral and psychologic symptoms of dementia. Clin. Geriatr. Med., 2003, 19(4), 799-824.
[http://dx.doi.org/10.1016/S0749-0690(03)00046-6] [PMID: 15024813]
[14]
Huang, Y.J.; Lin, C.H.; Lane, H.Y.; Tsai, G.E. NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s Disease. Curr. Neuropharmacol., 2012, 10(3), 272-285.
[http://dx.doi.org/10.2174/157015912803217288] [PMID: 23450042]
[15]
Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer’s disease. I: Disorders of thought content. Br. J. Psychiatry, 1990, 157, 72-76, 92-94.
[http://dx.doi.org/10.1192/bjp.157.1.72] [PMID: 2397365]
[16]
Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer’s disease. II: Disorders of perception. Br. J. Psychiatry, 1990, 157, 76-81, 92-94.
[http://dx.doi.org/10.1192/bjp.157.1.76] [PMID: 2397366]
[17]
Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer’s disease. III: Disorders of mood. Br. J. Psychiatry, 1990, 157, 81-86, 92-94.
[http://dx.doi.org/10.1192/bjp.157.1.81] [PMID: 2397367]
[18]
Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer’s disease. IV: Disorders of behaviour. Br. J. Psychiatry, 1990, 157, 86-94.
[http://dx.doi.org/10.1192/bjp.157.1.86] [PMID: 2397368]
[19]
Tariot, P.N.; Mack, J.L.; Patterson, M.B.; Edland, S.D.; Weiner, M.F.; Fillenbaum, G.; Blazina, L.; Teri, L.; Rubin, E.; Mortimer, J.A. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer’s Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer’s Disease. Am. J. Psychiatry, 1995, 152(9), 1349-1357.
[http://dx.doi.org/10.1176/ajp.152.9.1349] [PMID: 7653692]
[20]
Harwood, D.G.; Barker, W.W.; Ownby, R.L.; Duara, R. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 2000, 15(5), 393-400.
[http://dx.doi.org/10.1002/(SICI)1099-1166(200005)15:5<393:AID-GPS120>3.0.CO;2-O] [PMID: 10822237]
[21]
Savva, G.M.; Zaccai, J.; Matthews, F.E.; Davidson, J.E.; McKeith, I.; Brayne, C. Medical Research Council Cognitive Function and Ageing Study. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br. J. Psychiatry, 2009, 194(3), 212-219.
[http://dx.doi.org/10.1192/bjp.bp.108.049619] [PMID: 19252147]
[22]
Corbett, A.; Husebo, B.; Malcangio, M.; Staniland, A.; Cohen-Mansfield, J.; Aarsland, D.; Ballard, C. Assessment and treatment of pain in people with dementia. Nat. Rev. Neurol., 2012, 8(5), 264-274.
[http://dx.doi.org/10.1038/nrneurol.2012.53] [PMID: 22487749]
[23]
Zarow, C.; Lyness, S.A.; Mortimer, J.A.; Chui, H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol., 2003, 60(3), 337-341.
[http://dx.doi.org/10.1001/archneur.60.3.337] [PMID: 12633144]
[24]
Parvizi, J.; Van Hoesen, G.W.; Damasio, A. Selective pathological changes of the periaqueductal gray matter in Alzheimer’s disease. Ann. Neurol., 2000, 48(3), 344-353.
[http://dx.doi.org/10.1002/1531-8249(200009)48:3<344:AID-ANA9>3.0.CO;2-S] [PMID: 10976641]
[25]
Willis, W.D.; Westlund, K.N. Neuroanatomy of the pain system and of the pathways that modulate pain. J. Clin. Neurophysiol., 1997, 14(1), 2-31.
[http://dx.doi.org/10.1097/00004691-199701000-00002] [PMID: 9013357]
[26]
Scherder, E.J.; Sergeant, J.A.; Swaab, D.F. Pain processing in dementia and its relation to neuropathology. Lancet Neurol., 2003, 2(11), 677-686.
[http://dx.doi.org/10.1016/S1474-4422(03)00556-8] [PMID: 14572736]
[27]
Ossipov, M.H.; Dussor, G.O.; Porreca, F. Central modulation of pain. J. Clin. Invest., 2010, 120(11), 3779-3787.
[http://dx.doi.org/10.1172/JCI43766] [PMID: 21041960]
[28]
Han, J.S.; Bird, G.C.; Neugebauer, V. Enhanced group III mGluR-mediated inhibition of pain-related synaptic plasticity in the amygdala. Neuropharmacology, 2004, 46(7), 918-926.
[http://dx.doi.org/10.1016/j.neuropharm.2004.01.006] [PMID: 15081788]
[29]
Li, W.; Neugebauer, V. Differential roles of mGluR1 and mGluR5 in brief and prolonged nociceptive processing in central amygdala neurons. J. Neurophysiol., 2004, 91(1), 13-24.
[http://dx.doi.org/10.1152/jn.00485.2003] [PMID: 13679408]
[30]
Bourgeais, L.; Gauriau, C.; Bernard, J.F. Projections from the nociceptive area of the central nucleus of the amygdala to the forebrain: a PHA-L study in the rat. Eur. J. Neurosci., 2001, 14(2), 229-255.
[http://dx.doi.org/10.1046/j.0953-816x.2001.01640.x] [PMID: 11553276]
[31]
Husebo, B.S.; Strand, L.I.; Moe-Nilssen, R.; Husebo, S.B.; Ljunggren, A.E. Pain in older persons with severe dementia. Psychometric properties of the Mobilization-Observation-Behaviour-Intensity-Dementia (MOBID-2) pain scale in a clinical setting. Scand. J. Caring Sci., 2010, 24(2), 380-391.
[http://dx.doi.org/10.1111/j.1471-6712.2009.00710.x] [PMID: 20210897]
[32]
Ballard, C.; Howard, R. Neuroleptic drugs in dementia: benefits and harm. Nat. Rev. Neurosci., 2006, 7(6), 492-500.
[http://dx.doi.org/10.1038/nrn1926] [PMID: 16715057]
[33]
Schneider, L.S.; Dagerman, K.; Insel, P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry, 2006, 14(3), 191-210.
[http://dx.doi.org/10.1097/01.JGP.0000200589.01396.6d] [PMID: 16505124]
[34]
Ballard, C.G.; Gauthier, S.; Cummings, J.L.; Brodaty, H.; Grossberg, G.T.; Robert, P.; Lyketsos, C.G. Management of agitation and aggression associated with Alzheimer disease. Nat. Rev. Neurol., 2009, 5(5), 245-255.
[http://dx.doi.org/10.1038/nrneurol.2009.39] [PMID: 19488082]
[35]
Scuteri, D.; Morrone, L.A.; Rombola, L.; Avato, P.R.; Bilia, A.R.; Corasaniti, M.T.; Sakurada, S.; Sakurada, T.; Bagetta, G. Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Clinical Evidence and Possible Mechanisms. Evid. Based Complement. Alternat. Med., 2017, 2017, 9416305.
[http://dx.doi.org/10.1155/2017/9416305] [PMID: 28465709]
[36]
Husebo, B.S.; Ballard, C.; Sandvik, R.; Nilsen, O.B.; Aarsland, D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ, 2011, 343, d4065.
[http://dx.doi.org/10.1136/bmj.d4065] [PMID: 21765198]
[37]
Morrone, L.A.; Scuteri, D.; Rombolà, L.; Mizoguchi, H.; Bagetta, G. Opioids resistance in chronic pain management. Curr. Neuropharmacol., 2017, 15(3), 444-456.
[http://dx.doi.org/10.2174/1570159X14666161101092822] [PMID: 28503117]
[38]
Jimbo, D.; Kimura, Y.; Taniguchi, M.; Inoue, M.; Urakami, K. Effect of aromatherapy on patients with Alzheimer's disease. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2009, 9(4), 173-9.
[http://dx.doi.org/10.1111/j.1479-8301.2009.00299.x]
[39]
Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol., 1991, 82(4), 239-259.
[http://dx.doi.org/10.1007/BF00308809] [PMID: 1759558]
[40]
Gold, G.; Bouras, C.; Kövari, E.; Canuto, A.; Glaría, B.G.; Malky, A.; Hof, P.R.; Michel, J.P.; Giannakopoulos, P. Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol., 2000, 99(5), 579-582.
[http://dx.doi.org/10.1007/s004010051163] [PMID: 10805104]
[41]
Carnat, A.P.; Carnat, A.; Fraisse, D.; Lamaison, J.L. The aromatic and polyphenolic composition of lemon balm (Melissa Officinalis L. subsp. Officinalis) tea. Pharm. Acta Helv., 1998, 72, 301-305.
[http://dx.doi.org/10.1016/S0031-6865(97)00026-5]
[42]
Perry, E.K.; Pickering, A.T.; Wang, W.W.; Houghton, P.; Perry, N.S. Medicinal plants and Alzheimer’s disease: integrating ethnobotanical and contemporary scientific evidence. J. Altern. Complement. Med., 1998, 4(4), 419-428.
[http://dx.doi.org/10.1089/acm.1998.4.419] [PMID: 9884179]
[43]
Perry, E.K.; Pickering, A.T.; Wang, W.W.; Houghton, P.J.; Perry, N.S. Medicinal plants and Alzheimer’s disease: from ethnobotany to phytotherapy. J. Pharm. Pharmacol., 1999, 51(5), 527-534.
[http://dx.doi.org/10.1211/0022357991772808] [PMID: 10411211]
[44]
Wake, G.; Court, J.; Pickering, A.; Lewis, R.; Wilkins, R.; Perry, E. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J. Ethnopharmacol., 2000, 69(2), 105-114.
[http://dx.doi.org/10.1016/S0378-8741(99)00113-0] [PMID: 10687867]
[45]
Kennedy, D. O.; Wake, G.; Savelev, S.; Tildesley, N. T.; Perry, E. K.; Wesnes, K. A.; Scholey, A. B. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, 28(10), 1871-81.
[46]
Dastmalchi, K.; Ollilainen, V.; Lackman, P.; Boije af Gennäs, G.; Dorman, H.J.; Järvinen, P.P.; Yli-Kauhaluoma, J.; Hiltunen, R. Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorg. Med. Chem., 2009, 17(2), 867-871.
[http://dx.doi.org/10.1016/j.bmc.2008.11.034] [PMID: 19070498]
[47]
Berliocchi, L.; Russo, R.; Maiarù, M.; Levato, A.; Bagetta, G.; Corasaniti, M.T. Autophagy impairment in a mouse model of neuropathic pain. Mol. Pain, 2011, 7, 83.
[http://dx.doi.org/10.1186/1744-8069-7-83] [PMID: 22023914]
[48]
Yu, W.H.; Cuervo, A.M.; Kumar, A.; Peterhoff, C.M.; Schmidt, S.D.; Lee, J.H.; Mohan, P.S.; Mercken, M.; Farmery, M.R.; Tjernberg, L.O.; Jiang, Y.; Duff, K.; Uchiyama, Y.; Näslund, J.; Mathews, P.M.; Cataldo, A.M.; Nixon, R.A. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J. Cell Biol., 2005, 171(1), 87-98.
[http://dx.doi.org/10.1083/jcb.200505082] [PMID: 16203860]
[49]
Berliocchi, L.; Maiarù, M.; Varano, G.P.; Russo, R.; Corasaniti, M.T.; Bagetta, G.; Tassorelli, C. Spinal autophagy is differently modulated in distinct mouse models of neuropathic pain. Mol. Pain, 2015, 11, 3.
[http://dx.doi.org/10.1186/1744-8069-11-3] [PMID: 25645145]
[50]
Russo, R.; Cassiano, M.G.; Ciociaro, A.; Adornetto, A.; Varano, G.P.; Chiappini, C.; Berliocchi, L.; Tassorelli, C.; Bagetta, G.; Corasaniti, M.T. Role of D-Limonene in autophagy induced by bergamot essential oil in SH-SY5Y neuroblastoma cells. PLoS One, 2014, 9(11), e113682.
[http://dx.doi.org/10.1371/journal.pone.0113682] [PMID: 25419658]
[51]
Bagetta, G.; Morrone, L.A.; Rombolà, L.; Amantea, D.; Russo, R.; Berliocchi, L.; Sakurada, S.; Sakurada, T.; Rotiroti, D.; Corasaniti, M.T. Neuropharmacology of the essential oil of bergamot. Fitoterapia, 2010, 81(6), 453-461.
[http://dx.doi.org/10.1016/j.fitote.2010.01.013] [PMID: 20093169]
[52]
Kuwahata, H.; Komatsu, T.; Katsuyama, S.; Corasaniti, M.T.; Bagetta, G.; Sakurada, S.; Sakurada, T.; Takahama, K. Peripherally injected linalool and bergamot essential oil attenuate mechanical allodynia via inhibiting spinal ERK phosphorylation. Pharmacol. Biochem. Behav., 2013, 103(4), 735-741.
[http://dx.doi.org/10.1016/j.pbb.2012.11.003] [PMID: 23159543]
[53]
Farmacopea Ufficiale Italiana. In: Droghe Vegetali e Preparazioni (IX Edizione); Istituto Poligrafico e Zecca dello Stato, 1991; p. 75.
[54]
Corasaniti, M.T.; Maiuolo, J.; Maida, S.; Fratto, V.; Navarra, M.; Russo, R.; Amantea, D.; Morrone, L.A.; Bagetta, G. Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro. Br. J. Pharmacol., 2007, 151(4), 518-529.
[http://dx.doi.org/10.1038/sj.bjp.0707237] [PMID: 17401440]
[55]
Sakurada, T.; Mizoguchi, H.; Kuwahata, H.; Katsuyama, S.; Komatsu, T.; Morrone, L.A.; Corasaniti, M.T.; Bagetta, G.; Sakurada, S. Intraplantar injection of bergamot essential oil induces peripheral antinociception mediated by opioid mechanism. Pharmacol. Biochem. Behav., 2011, 97(3), 436-443.
[http://dx.doi.org/10.1016/j.pbb.2010.09.020] [PMID: 20932858]
[56]
Kim, S.H.; Chung, J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain, 1992, 50(3), 355-363.
[http://dx.doi.org/10.1016/0304-3959(92)90041-9] [PMID: 1333581]
[57]
Malmberg, A.B.; Basbaum, A.I. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain, 1998, 76(1-2), 215-222.
[http://dx.doi.org/10.1016/S0304-3959(98)00045-1] [PMID: 9696476]
[58]
Katsuyama, S.; Otowa, A.; Kamio, S.; Sato, K.; Yagi, T.; Kishikawa, Y.; Komatsu, T.; Bagetta, G.; Sakurada, T.; Nakamura, H. Effect of plantar subcutaneous administration of bergamot essential oil and linalool on formalin-induced nociceptive behavior in mice. Biomed. Res., 2015, 36(1), 47-54.
[http://dx.doi.org/10.2220/biomedres.36.47] [PMID: 25749150]
[59]
Abbadie, C.; Taylor, B.K.; Peterson, M.A.; Basbaum, A.I. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain, 1997, 69(1-2), 101-110.
[http://dx.doi.org/10.1016/S0304-3959(96)03285-X] [PMID: 9060019]
[60]
Abram, S.E.; Yaksh, T.L. Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. Anesthesiology, 1994, 80(2), 383-391.
[http://dx.doi.org/10.1097/00000542-199402000-00018] [PMID: 8311320]
[61]
Ji, R.R.; Baba, H.; Brenner, G.J.; Woolf, C.J. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat. Neurosci., 1999, 2(12), 1114-1119.
[http://dx.doi.org/10.1038/16040] [PMID: 10570489]
[62]
Rombolà, L.; Corasaniti, M.T.; Rotiroti, D.; Tassorelli, C.; Sakurada, S.; Bagetta, G.; Morrone, L.A. Effects of systemic administration of the essential oil of bergamot (BEO) on gross behaviour and EEG power spectra recorded from the rat hippocampus and cerebral cortex. Funct. Neurol., 2009, 24(2), 107-112.
[PMID: 19775539]
[63]
Morrone, L.A.; Rombolà, L.; Pelle, C.; Corasaniti, M.T.; Zappettini, S.; Paudice, P.; Bonanno, G.; Bagetta, G. The essential oil of bergamot enhances the levels of amino acid neurotransmitters in the hippocampus of rat: implication of monoterpene hydrocarbons. Pharmacol. Res., 2007, 55(4), 255-262.
[http://dx.doi.org/10.1016/j.phrs.2006.11.010] [PMID: 17196823]
[64]
Attwell, D.; Barbour, B.; Szatkowski, M. Nonvesicular release of neurotransmitter. Neuron, 1993, 11(3), 401-407.
[http://dx.doi.org/10.1016/0896-6273(93)90145-H] [PMID: 8104430]
[65]
Levi, G.; Raiteri, M. Carrier-mediated release of neurotransmitters. Trends Neurosci., 1993, 16(10), 415-419.
[http://dx.doi.org/10.1016/0166-2236(93)90010-J] [PMID: 7504357]
[66]
Manns, I.D.; Alonso, A.; Jones, B.E. Rhythmically discharging basal forebrain units comprise cholinergic, GABAergic, and putative glutamatergic cells. J. Neurophysiol., 2003, 89(2), 1057-1066.
[http://dx.doi.org/10.1152/jn.00938.2002] [PMID: 12574480]
[67]
Boddeke, H.W.; Best, R.; Boeijinga, P.H. Synchronous 20 Hz rhythmic activity in hippocampal networks induced by activation of metabotropic glutamate receptors in vitro. Neuroscience, 1997, 76(3), 653-658.
[PMID: 9135039]
[68]
Pittaluga, A. Presynaptic release-regulating mglu1 receptors in central nervous system. Front. Pharmacol., 2016, 7, 295.
[http://dx.doi.org/10.3389/fphar.2016.00295] [PMID: 27630571]
[69]
(WHO), W. H. O., Dementia: A Public Health Priority; WHO: Geneva, 2012.
[70]
Achterberg, W.P.; Pieper, M.J.; van Dalen-Kok, A.H.; de Waal, M.W.; Husebo, B.S.; Lautenbacher, S.; Kunz, M.; Scherder, E.J.; Corbett, A. Pain management in patients with dementia. Clin. Interv. Aging, 2013, 8, 1471-1482.
[http://dx.doi.org/10.2147/CIA.S36739] [PMID: 24204133]
[71]
Fratiglioni, L.; De Ronchi, D.; Agüero-Torres, H. Worldwide prevalence and incidence of dementia. Drugs Aging, 1999, 15(5), 365-375.
[http://dx.doi.org/10.2165/00002512-199915050-00004] [PMID: 10600044]
[72]
Laurila, J.V.; Pitkala, K.H.; Strandberg, T.E.; Tilvis, R.S. Detection and documentation of dementia and delirium in acute geriatric wards. Gen. Hosp. Psychiatry, 2004, 26(1), 31-35.
[http://dx.doi.org/10.1016/j.genhosppsych.2003.08.003] [PMID: 14757300]
[73]
Sampson, E.L.; Blanchard, M.R.; Jones, L.; Tookman, A.; King, M. Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br. J. Psychiatry, 2009, 195(1), 61-66.
[http://dx.doi.org/10.1192/bjp.bp.108.055335] [PMID: 19567898]
[74]
Sampson, E.L.; White, N.; Lord, K.; Leurent, B.; Vickerstaff, V.; Scott, S.; Jones, L. Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: a longitudinal cohort study. Pain, 2015, 156(4), 675-683.
[http://dx.doi.org/10.1097/j.pain.0000000000000095] [PMID: 25790457]
[75]
Tosato, M.; Lukas, A.; van der Roest, H.G.; Danese, P.; Antocicco, M.; Finne-Soveri, H.; Nikolaus, T.; Landi, F.; Bernabei, R.; Onder, G. Association of pain with behavioral and psychiatric symptoms among nursing home residents with cognitive impairment: results from the SHELTER study. Pain, 2012, 153(2), 305-310.
[http://dx.doi.org/10.1016/j.pain.2011.10.007] [PMID: 22093815]
[76]
Ahn, H.; Horgas, A. The relationship between pain and disruptive behaviors in nursing home residents with dementia. BMC Geriatr., 2013, 13, 14.
[http://dx.doi.org/10.1186/1471-2318-13-14] [PMID: 23399452]
[77]
Sakurada, T.; Kuwahata, H.; Katsuyama, S.; Komatsu, T.; Morrone, L.A.; Corasaniti, M.T.; Bagetta, G.; Sakurada, S. Intraplantar injection of bergamot essential oil into the mouse hindpaw: effects on capsaicin-induced nociceptive behaviors. Int. Rev. Neurobiol., 2009, 85, 237-248.
[http://dx.doi.org/10.1016/S0074-7742(09)85018-6] [PMID: 19607974]
[78]
Chizh, B.A.; Headley, P.M. NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses. Curr. Pharm. Des., 2005, 11(23), 2977-2994.
[http://dx.doi.org/10.2174/1381612054865082] [PMID: 16178757]
[79]
Eide, P.K. Wind-up and the NMDA receptor complex from a clinical perspective. Eur. J. Pain, 2000, 4(1), 5-15.
[http://dx.doi.org/10.1053/eujp.1999.0154] [PMID: 10833550]
[80]
Park, B.Y.; Park, S.H.; Kim, W.M.; Yoon, M.H.; Lee, H.G. Antinociceptive Effect of Memantine and Morphine on Vincristine-induced Peripheral Neuropathy in Rats. Korean J. Pain, 2010, 23(3), 179-185.
[http://dx.doi.org/10.3344/kjp.2010.23.3.179] [PMID: 20830263]
[81]
Chevaleyre, V.; Takahashi, K.A.; Castillo, P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci., 2006, 29, 37-76.
[http://dx.doi.org/10.1146/annurev.neuro.29.051605.112834] [PMID: 16776579]
[82]
Lau, B.K.; Vaughan, C.W. Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray. Mol. Pharmacol., 2008, 74(5), 1392-1398.
[http://dx.doi.org/10.1124/mol.108.045872] [PMID: 18678620]
[83]
Fields, H.L.; Basbaum, A.I.; Heinricher, M.M. Central nervous systems mechanisms of pain modulation. In: Textbook of Pain,; eds., M. S. A. K. M., Ed. Elsevier, Churchill Livingston, Philadelphia, PA,. , 2006; pp. 125-142.
[http://dx.doi.org/10.1016/B0-443-07287-6/50012-6]
[84]
Coggeshall, R.E.; Zhou, S.; Carlton, S.M. Opioid receptors on peripheral sensory axons. Brain Res., 1997, 764(1-2), 126-132.
[http://dx.doi.org/10.1016/S0006-8993(97)00446-0] [PMID: 9295201]
[85]
Iremonger, K.J.; Kuzmiski, J.B.; Baimoukhametova, D.V.; Bains, J.S. Dual regulation of anterograde and retrograde transmission by endocannabinoids. J. Neurosci., 2011, 31(33), 12011-12020.
[http://dx.doi.org/10.1523/JNEUROSCI.2925-11.2011] [PMID: 21849561]
[86]
Walsh, R.N.; Cummins, R.A. The Open-Field Test: a critical review. Psychol. Bull., 1976, 83(3), 482-504.
[http://dx.doi.org/10.1037/0033-2909.83.3.482] [PMID: 17582919]
[87]
Pellow, S.; Chopin, P.; File, S.E.; Briley, M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 1985, 14(3), 149-167.
[http://dx.doi.org/10.1016/0165-0270(85)90031-7] [PMID: 2864480]
[88]
Porsolt, R.D.; Bertin, A.; Jalfre, M. “Behavioural despair” in rats and mice: strain differences and the effects of imipramine. Eur. J. Pharmacol., 1978, 51(3), 291-294.
[http://dx.doi.org/10.1016/0014-2999(78)90414-4] [PMID: 568552]
[89]
Detke, M.J.; Lucki, I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav. Brain Res., 1996, 73(1-2), 43-46.
[http://dx.doi.org/10.1016/0166-4328(96)00067-8] [PMID: 8788475]
[90]
Rombolà, L.; Tridico, L.; Scuteri, D.; Sakurada, T.; Sakurada, S.; Mizoguchi, H.; Avato, P.; Corasaniti, M.T.; Bagetta, G.; Morrone, L.A. Bergamot Essential oil attenuates anxiety-like behaviour in rats. Molecules, 2017, 22(4), E614.
[http://dx.doi.org/10.3390/molecules22040614] [PMID: 28398260]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 20
Year: 2019
Page: [3764 - 3774]
Pages: 11
DOI: 10.2174/0929867325666180307115546
Price: $58

Article Metrics

PDF: 32
HTML: 2
PRC: 1